- Home
- CLSK vs AAPG Comparison
CLSK vs AAPG Comparison
Compare CLSK & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLSK
- AAPG
- Stock Information
- Founded
- CLSK 1987
- AAPG 2009
- Country
- CLSK United States
- AAPG China
- Employees
- CLSK N/A
- AAPG N/A
- Industry
- CLSK Finance: Consumer Services
- AAPG Biotechnology: Pharmaceutical Preparations
- Sector
- CLSK Finance
- AAPG Health Care
- Exchange
- CLSK Nasdaq
- AAPG Nasdaq
- Market Cap
- CLSK 2.7B
- AAPG 2.2B
- IPO Year
- CLSK N/A
- AAPG 2025
- Fundamental
- Price
- CLSK $8.63
- AAPG $24.40
- Analyst Decision
- CLSK Strong Buy
- AAPG Buy
- Analyst Count
- CLSK 7
- AAPG 1
- Target Price
- CLSK $21.00
- AAPG N/A
- AVG Volume (30 Days)
- CLSK 28.3M
- AAPG 14.1K
- Earning Date
- CLSK 05-08-2025
- AAPG 06-10-2025
- Dividend Yield
- CLSK N/A
- AAPG N/A
- EPS Growth
- CLSK N/A
- AAPG N/A
- EPS
- CLSK N/A
- AAPG N/A
- Revenue
- CLSK $537,401,000.00
- AAPG $134,352,180.00
- Revenue This Year
- CLSK $109.65
- AAPG N/A
- Revenue Next Year
- CLSK $35.05
- AAPG $389.09
- P/E Ratio
- CLSK N/A
- AAPG N/A
- Revenue Growth
- CLSK 89.47
- AAPG 341.77
- 52 Week Low
- CLSK $6.45
- AAPG $16.50
- 52 Week High
- CLSK $20.64
- AAPG $26.55
- Technical
- Relative Strength Index (RSI)
- CLSK 45.66
- AAPG N/A
- Support Level
- CLSK $9.14
- AAPG N/A
- Resistance Level
- CLSK $10.09
- AAPG N/A
- Average True Range (ATR)
- CLSK 0.67
- AAPG 0.00
- MACD
- CLSK -0.14
- AAPG 0.00
- Stochastic Oscillator
- CLSK 5.86
- AAPG 0.00
About CLSK CleanSpark Inc.
Cleanspark Inc is a bitcoin mining company. Through CleanSpark, Inc., and the Company's wholly owned subsidiaries, the company mines bitcoin. The company entered the bitcoin mining industry through its acquisition of ATL. Bitcoin mining is the sole reportable segment of the company.
About AAPG Ascentage Pharma Group International American Depository Shares
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.